Boehringer Ingelheim and Eli Lilly and Co. have begun a clinical trial to investigate empagliflozin for the treatment of adults with chronic heart failure.
The Emperor HF clinical trial program will involve not only adults with Type 2 diabetes who have heart failure, but also heart failure patients who do not have diabetes, according to a press release.
"Heart failure is a global health burden," Dr. Milton Packer of Baylor Heart and Vascular Institute, Baylor University Medical Center, said in the release. "We need to explore new treatment options, especially for those types of heart failure where treatments are currently limited."
Emperor HF will include approximately 7,000 patients with chronic heart failure within two trials.
"The Empa-Reg Outcome trial demonstrated a significant reduction in the risk of cardiovascular death with empagliflozin in adults with Type 2 diabetes and cardiovascular disease," Packer said. "And now these new Emperor HF clinical trials will take a dedicated look at the effects of empagliflozin in heart failure patients."
